Optimi Health Corp. Common Shares(OPTH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.25
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for OPTH

11/13/2026: OPTH (1-star) is currently NOT-A-BUY. Pass it for now.

Optimi Health Corp. is a small-cap, speculative company operating in the early-stage psychedelics and wellness industry. Its main strength lies in its licensed production facilities and ability to provide GMP-grade synthetic psilocybin for clinical trials. The primary investment opportunity centers on the potential for psilocybin to become a standard treatment for mental health conditions, though the stock faces significant risks, including regulatory uncertainty and high cash burn. Due to its speculative nature, the stock is best suited for high-risk-tolerant investors. Key developments to monitor include updates on clinical trial outcomes and any shifts in international regulations regarding the medical use of psychedelics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high growth potential linked to the psychedelics industry but carries significant execution risk.
Momentum investorWeak fitMomentum is highly conditional on speculative news flow and sector-wide sentiment.
Value investorWeak fitThe company is in an early, high-expenditure phase, making traditional value metrics inapplicable.
Dividend investorWeak fitNo dividend is paid, and none are expected in the near term.
Low-risk investorWeak fitThe stock is highly volatile and exposed to significant regulatory and clinical trial risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is susceptible to large price swings due to news-driven sentiment in the speculative psychedelics market.
Valuation riskHighValuations are highly speculative as they depend on future medical breakthroughs that are not guaranteed.
Competition risk (Biotech/Pharma)Medium / highWell-funded biotech firms may outpace the company in clinical research and IP development.
Business qualityMediumWhile the company has achieved regulatory milestones, the business model is still proving its path to profitability.
Dividend incomeLow / noneThe company does not provide income to shareholders.
Execution riskMedium / highThe ability to successfully scale GMP production and gain regulatory approvals is critical to success.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 12.88M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 37.1K shares
Beta 1.6
52 Weeks Range 1.90 - 8.84
Updated Date 11/14/2026
52 Weeks Range 1.90 - 8.84
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.56

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 38.92%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
OPTH receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
OPTH has moderate overall fundamentals (3 stars), with weak financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+38.4%) is partially offset by weak cash generation (FCF margin -636.3%), moderate revenue growth (+9.5%), weak profitability (net margin -870.8%).

Financial Health Rating

★★★★★
OPTH's financial health is weak, with the relatively strongest area being soft cash strength, including free-cash-flow generation (-636.3% of revenue). Operating efficiency is weak (1 stars), which helps explain the 1-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is OPTH's strongest growth driver at +38.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+38.4%, strong) is also strong, while revenue growth (+9.5%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 10.2% and approximately 81.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 12.66% supports management-shareholder alignment.

Top 5 Institutional Investors

Yorkville Advisors Global, LP 3.48%
Mariner Wealth Advisors LLC 2.14%
AdvisorShares Investments, LLC 1.80%
TWO SIGMA SECURITIES, LLC 0.19%
UBS Group AG 0.10%

Unit Economics (Per $1K Revenue)

★★★★★
OPTH generates approximately $-4,864 of gross profit, $-10,623 of operating income, and $-6,363 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
OPTH has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Functional MushroomsConsumer wellness products sold through retail channels.The company generates steady, non-psychedelic revenue from health supplements.
Psilocybin SupplyLicensed supply of GMP-grade substances for clinical research.This is a high-growth, high-risk segment tied to pharmaceutical research breakthroughs.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 7.29M
Price to Sales(TTM) 73.34
Enterprise Value 7.29M
Price to Sales(TTM) 73.34
Enterprise Value to Revenue 57.21
Enterprise Value to EBITDA -
Shares Outstanding 5.73M
Shares Floating 4.65M
Shares Outstanding 5.73M
Shares Floating 4.65M
Percent Insiders 12.66
Percent Institutions 10.17

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.